Avadel's hospital product candidate accepted for priority review by US FDA
Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Avadel Pharmaceuticals PLC said the U.S. Food and Drug Administration accepted the new drug application for the company's hospital product candidate AV001 and granted it priority review.
The U.S. regulator will decide on Avadel's product candidate by Sept. 15. The Dublin-based company did not disclose what indication the product will be used for.